1. Tae BS, Balpukov U, Cho SY, Jeong CW. Eleven-year cumulative incidence and estimated lifetime prevalence of urolithiasis in korea: a national health insurance service-national sample cohort based study. J Korean Med Sci 2018;33:e13.
2. Strohmaier WL. Course of calcium stone disease without treat-ment. What can we expect? Eur Urol 2000;37:339-344.
3. Uribarri J, Oh MS, Carroll HJ. The first kidney stone. Ann Intern Med 1989;111:1006-1009.
4. Saigal CS, Joyce G, Timilsina AR; Urologic Diseases in America Project. Direct and indirect costs of nephrolithiasis in an emplo-yed population: opportunity for disease management? Kidney Int 2005;68:1808-1814.
5. Pearle MS, Asplin JR, Coe FL, Rodgers A, Worcester EM. Medi-cal management of urolithiasis. In: Proceedings of the 2nd International Consultation on Stone Disease; 2007 Sep 5; Paris, France. Paris: Health Publications; 2008.
6. Norman RW, Bath SS, Robertson WG, Peacock M. When should patients with symptomatic urinary stone disease be evaluated metabolically? J Urol 1984;132:1137-1139.
7. Turk C, Skolarikos A, Neisius A, Petrik A, Seitz C, Thomas K. EAU guidelines on urolithiasis 2019. Arnhem: European Asso-ciation of Urology; 2019.
11. Fann CY, Huang PC, Yen AM, Chen HH. Patient utility mea-surement for managing ureteral stones: a modified standard gamble approach. Value Health Reg Issues 2012;1:87-92.
14. Shekarriz B, Stoller ML. Uric acid nephrolithiasis: current con-cepts and controversies. J Urol 2002;168:1307-1314.
17. Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY. Association of urinary pH with body weight in nephrolithiasis. Kidney Int 2004;65:1422-1425.
18. Pak CY, Sakhaee K, Fuller C. Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int 1986;30:422-428.
19. Leusmann DB, Blaschke R, Schmandt W. Results of 5,035 stone analyses: a contribution to epidemiology of urinary stone dis-ease. Scand J Urol Nephrol 1990;24:205-210.
20. Milliner DS, Murphy ME. Urolithiasis in pediatric patients. Mayo Clin Proc 1993;68:241-248.
21. Kramer G, Klingler HC, Steiner GE. Role of bacteria in the development of kidney stones. Curr Opin Urol 2000;10:35-38.
22. Silverman DE, Stamey TA. Management of infection stones: the Stanford experience. Medicine (Baltimore) 1983;62:44-51.
23. Preminger GM, Baker S, Peterson R, Poindexter J, Pak CY. Hypomagnesiuric hypocitraturia: an apparent new entity for calcium nephrolithiasis. J Lithotripsy Stone Dis 1989;1:22-25.
24. Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996;155:839-843.
26. Odvina CV. Comparative value of orange juice versus lemonade in reducing stone-forming risk. Clin J Am Soc Nephrol 2006;1:1269-1274.
27. Koff SG, Paquette EL, Cullen J, Gancarczyk KK, Tucciarone PR, Schenkman NS. Comparison between lemonade and potassium citrate and impact on urine pH and 24-hour urine parameters in patients with kidney stone formation. Urology 2007;69:1013-1016.
29. Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U, Novarini A. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002;346:77-84.
30. Penniston KL, Nakada SY. Effect of dietary changes on urinary oxalate excretion and calcium oxalate supersaturation in patients with hyperoxaluric stone formation. Urology 2009;73:484-489.
31. Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int 2008;73:489-496.
33. Taylor EN, Stampfer MJ, Curhan GC. Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up. J Am Soc Nephrol 2004;15:3225-3232.
34. Traxer O, Huet B, Poindexter J, Pak CY, Pearle MS. Effect of ascorbic acid consumption on urinary stone risk factors. J Urol 2003;170:397-401.
35. Meschi T, Maggiore U, Fiaccadori E, Schianchi T, Bosi S, Adorni G, Ridolo E, Guerra A, Allegri F, Novarini A, Borghi L. The effect of fruits and vegetables on urinary stone risk factors. Kidney Int 2004;66:2402-2410.
39. Heilberg IP, Goldfarb DS. Optimum nutrition for kidney stone disease. Adv Chronic Kidney Dis 2013;20:165-174.
40. Remer T, Manz F. Potential renal acid load of foods and its influence on urine pH. J Am Diet Assoc 1995;95:791-797.
41. de Planter Bowes A, Church HN, Pennington JA. Bowes and Churchʼs food values of portions commonly used. 17th ed. Philadelphia: Lippincott Williams and Wilkins; 1998.
42. Mahan LK, Escott-Stump S. Krauseʼs food, nutrition, and diet therapy. Philadelphia: WB Saunders; 2000.
43. Saravakos P, Kokkinou V, Giannatos E. Cystinuria: current diagnosis and management. Urology 2014;83:693-699.
44. Rodriguez LM, Santos F, Malaga S, Martinez V. Effect of a low sodium diet on urinary elimination of cystine in cystinuric children. Nephron 1995;71:416-418.
45. Lindell A, Denneberg T, Edholm E, Jeppsson JO. The effect of sodium intake on cystinuria with and without tiopronin treatment. Nephron 1995;71:407-415.
46. Jaeger P, Portmann L, Saunders A, Rosenberg LE, Thier SO. Anticystinuric effects of glutamine and of dietary sodium restriction. N Engl J Med 1986;315:1120-1123.
47. Parks JH, Goldfisher E, Asplin JR, Coe FL. A single 24-hour urine collection is inadequate for the medical evaluation of nephrolithiasis. J Urol 2002;167:1607-1612.
49. Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, Brasure M, Kane RL, Ouellette J, Monga M. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med 2013;158:535-543.
50. Sakhaee K, Nicar M, Hill K, Pak CY. Contrasting effects of potassium citrate and sodium citrate therapies on urinary che-mistries and crystallization of stone-forming salts. Kidney Int 1983;24:348-352.
51. Pak CY, Peterson R, Sakhaee K, Fuller C, Preminger G, Reisch J. Correction of hypocitraturia and prevention of stone formation by combined thiazide and potassium citrate therapy in thiazide-unresponsive hypercalciuric nephrolithiasis. Am J Med 1985;79:284-288.
52. Lemann J Jr, Gray RW, Pleuss JA. Potassium bicarbonate, but not sodium bicarbonate, reduces urinary calcium excretion and improves calcium balance in healthy men. Kidney Int 1989;35:688-695.
53. Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY. Randomized double-blind study of potassium citrate in idiopathic hypoci-traturic calcium nephrolithiasis. J Urol 1993;150:1761-1764.
54. Ettinger B, Tang A, Citron JT, Livermore B, Williams T. Ran-domized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 1986;315:1386-1389.
55. Favus MJ, Coe FL. The effects of allopurinol treatment on stone formation on hyperuricosuric calcium oxalate stone-formers. Scand J Urol Nephrol Suppl 1980;53:265-271.
56. Norman RW. Metabolic evaluation of stone disease patients: a practical approach. Curr Opin Urol 2001;11:347-351.
57. Lifshitz DA, Shalhav AL, Lingeman JE, Evan AP. Metabolic evaluation of stone disease patients: a practical approach. J Endourol 1999;13:669-678.
58. Low RK, Stoller ML. Uric acid-related nephrolithiasis. Urol Clin North Am 1997;24:135-148.
59. Maalouf NM, Cameron MA, Moe OW, Sakhaee K. Novel insights into the pathogenesis of uric acid nephrolithiasis. Curr Opin Nephrol Hypertens 2004;13:181-189.
60. Barbey F, Joly D, Rieu P, Mejean A, Daudon M, Jungers P. Medical treatment of cystinuria: critical reappraisal of long-term results. J Urol 2000;163:1419-1423.
61. Martinez-Pineiro JA, de Iriarte EG, Armero AH. The problem of recurrences and infection after surgical removal of staghorn calculi. Eur Urol 1982;8:94-101.
62. Jarrar K, Boedeker RH, Weidner W. Struvite stones: long term follow up under metaphylaxis. Ann Urol (Paris) 1996;30:112-117.
63. Griffith DP, Gleeson MJ, Lee H, Longuet R, Deman E, Earle N. Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi. Eur Urol 1991;20:243-247.
64. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005;293:455-462.
65. Powell CR, Stoller ML, Schwartz BF, Kane C, Gentle DL, Bruce JE, Leslie SW. Impact of body weight on urinary electrolytes in urinary stone formers. Urology 2000;55:825-830.
66. Ekeruo WO, Tan YH, Young MD, Dahm P, Maloney ME, Mathias BJ, Albala DM, Preminger GM. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients. J Urol 2004;172:159-163.
67. Abate N, Chandalia M, Cabo-Chan AV Jr, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 2004;65:386-392.
68. Lee YC, Huang SP, Juan YS, Huang TY, Liu CC. Impact of metabolic syndrome and its components on kidney stone in aging Taiwanese males. Aging Male 2016;19:197-201.
69. Heidenreich A, Desgrandschamps F, Terrier F. Modern appro-ach of diagnosis and management of acute flank pain: review of all imaging modalities. Eur Urol 2002;41:351-362.
71. Sameh WM. Value of intravenous urography before shockwave lithotripsy in the treatment of renal calculi: a randomized study. J Endourol 2007;21:574-577.